WiSE CRT Is Beneficial for Heart Failure Patients as a Rescue Therapy: Evidence From a Meta-Analysis

Jiehui Cang, Yaowu Liu, Didi Zhu, Shangshang Liu, Junxian Shen, Hongyu Miao, Qianxing Zhou and Long Chen*

Department of Cardiology, Zhongda Hospital of Southeast University, Nanjing, China

Background: Leadless endocardial left ventricular (LV) pacing resynchronization therapy is a novel solution for patients with heart failure (HF) in whom conventional cardiac resynchronization therapy (CRT) failed.

Methods: PubMed and the Cochrane Library were searched for relevant cohort studies. Clinical outcomes of interest such as ejection fraction (EF), QRS duration (QRSD), and left ventricular end-systolic volume (LVESV) were extracted and analyzed.

Results: Five studies involving 175 HF patients for WiSE CRT were included, and patients were followed-up for 6 months. The implanted success rate ranged from 76.5 to 100%. WiSE CRT resulted in significantly narrower QRSD [mean difference (MD): −38.21 ms, 95% confidence interval (CI): −44.36 to −32.07, p < 0.001], improved left ventricular ejection fraction (MD: 6.07%, 95% CI: 4.43 to 7.71, I² = 0%, p < 0.001), reduced left ventricular end-systolic volume (MD: −23.47 ml, 95% CI: −37.18 to −9.13, p < 0.001), and reduced left ventricular end-diastolic volume (MD: −24.02 ml, 95% CI: −37.01 to −11.03, p = 0.02).

Conclusion: Evidence from current studies suggests that leadless endocardial LV pacing resynchronization is effective for HF patients who failed conventional CRT or needed a device upgrade, and it may be an interesting rescue therapy.

Keywords: WiSE system, CRT, leadless cardiac pacing, endocardial pacing, heart failure

INTRODUCTION
Cardiac resynchronization therapy (CRT) has been proven to be an effective way to improve the prognosis and mortality of patients with cardiac dysynchrony and heart failure (HF), which can be accomplished via biventricular pacing. Benefits, as there have been, 30–40% of patients do not respond to this conventional CRT (1). A metaanalysis including 150 consecutive CRT papers showed that the average rate of non-responders to CRT was about 34% (2). The common causes for the failure of traditional CRT include anatomical variations and high pacing threshold (3, 4).

Wireless stimulation endocardially CRT (WiSE CRT) system (EBR Systems, Sunnyvale, CA) is a kind of novel technology that has been approved for commercial use in Europe (5). The WiSE CRT system can pace the left ventricle via an endocardial receiver electrode which is placed in the left ventricle (instead of implanting a lead) and is powered wirelessly by a subcutaneous ultrasound pulse generator. The transmitter placed subcutaneously sends ultrasound to an electrode in the left ventricle, which converts the ultrasound waves into an electrical stimulation potential.
The transmitter is connected to the battery via a cable that serves as a source of energy (6). With a very short delay (3–10 ms), the transmitter can send a preprogrammed ultrasonic pulse acoustically to the electrode. The electrode converts the ultrasonic energy into electrical energy, which is used to activate the left ventricle. Stimulation can be simultaneous and biventricular due to the endocardial stimulation site. Theoretically speaking, all cardiac stimulation systems (pacemakers, defibrillators, and “leadless” pacemakers) available in the market can be implanted apart from subcutaneously implanted cardioverter-defibrillator (S-ICD), which currently does not allow ventricular stimulation.

The potential benefit of WiSE CRT, when compared with conventional CRT, is the ability to pace anywhere and provide targeted pacing without consideration of specific implantation site in LV, which will simplify the implant procedure and reduce the operation time (7, 8). Also, there is no need for long-time anticoagulant therapy after implantation, which may make the management of patients more convenient. Recent studies have shown that WiSE CRT could achieve narrower QRS duration (QRSd) and higher ejection fraction (EF) in those patients who failed to conventional CRT or were defined as non-responders to conventional CRT (5, 9–12). Whether WiSE CRT could help HF patients is unclear, so we conducted the meta-analysis of this novel technology to explore whether patients can benefit from WiSE CRT as a way of rescue therapy.

METHODS

Search Strategy

We systematically searched medical databases of PubMed and Cochrane library up to October 30, 2021, without publication status restriction. The search keywords included “WiSE or leadless” or “resynchronization” without any language restriction.

Study Selection

Two independent authors (Jiehui Cang and Yaowu Liu) filtered the studies fulfilling the following inclusion and exclusion criteria, and discrepancies were adjudicated by consensus and discussion with the third reviewer (Long Chen):

1. Trials including patients who failed conventional CRT procedure or were defined as no-responding to CRT were included or those who were previously implanted with pacemakers/ICD and met standard indications for CRT, referred to as an upgrade, were included. All patients receiving implantation of WiSE CRT were included in this meta-analysis.

2. Clinical trials including at least more than 5 patients were included. We excluded case-control studies, historically controlled studies, and crosssectional studies.

3. Outcomes of interest: ejection fraction (EF), QRS duration (QRSd), left ventricular end-systolic volume (LVESV) were included. However, in these outcomes, EF, rather than New York Heart Association (NYHA) class was compulsory.

4. Articles published as full-length articles in English were included.

5. When duplications of the data were found, the results of the most recent publications with longer follow-up durations were included in the meta-analysis.

Data Extraction and Quality Evaluation

After the inclusion of studies, indications of interest were extracted by Jiehui Cang. The extracted data included the details of studies and patient characteristics; LVEF, LVESD, LVEDD, and QRSd at baseline and 6-month follow-up in patients receiving WiSE CRT. The quality of non-randomized controlled studies was evaluated with the Newcastle–Ottawa Scale (NOS) (13).

Statistical Analyses

Review Manager 5.3 (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, DK) was used to analyze the extracted statistics. Categorical variables were estimated and presented as the overall proportion and confidence intervals (CIs). Continuous variables were estimated by mean difference (MD) and presented as the overall average values and CI. Statistical heterogeneity was conducted by calculating $I^2$, and $I^2 > 50\%$ was considered to indicate significant heterogeneity (14). When heterogeneity was present, sensitivity and subgroup analyses were performed to explore the possible causes. Publication bias was evaluated by visual inspection of asymmetry in funnel plots (15).

RESULTS

Searching Results

The process of literature searching is indicated in Figure 1. A total of 128 records were received by initial searching. A total of 15 articles were left after screening the title and abstract. The remaining records were checked by full-text review. Finally, five studies were included in the analysis (5, 9–12).

Study Characteristics and Quality Evaluation

Overall, five single-arm studies including 175 HF patients were analyzed. All studies focusing on WiSE CRT in selected HF patients were performed between 2014 and 2021. All included patients were those who failed conventional CRT procedures or were defined as no-responding to CRT or needed a device upgrade. One retrospective study focused on the combination of Micra and WiSE CRT (11). All studies have recorded EF during follow-up. However, none of them reported procedure time or X-ray exposure time. Patients were followed for 6 months in all the included studies. The quality of five studies with the NOS ranging from 6 to 8 points, as is concluded in Table 1, was generally good.

Electrophysiology Assessment

Four studies recorded QRSd at both baseline and follow-up (Figure 2A) (5, 9, 11, 12). The average QRSd decreased significantly (MD = −38.21 ms, 95% CI: −44.36 to −32.07, $p < 0.001$) after implantation of WiSE CRT. The heterogeneity among studies was high ($I^2 = 74\%$). Neither subgroup analysis...
nor sensitivity analysis could not significantly reduce the heterogeneity, and hence we decided to exclude none of them. One study additionally showed high R-wave amplitude (5.6 ± 3.2 mV) and low electrical pacing threshold (1.6 ± 1.0 V), respectively (10).

**Echocardiography Assessment**
All five studies included the assessment of LVEF after implantation of WiSE CRT, which indicated that WiSE CRT could improve cardiac function of selected patients with HF (MD = 6.07%, 95% CI: 4.43–7.71, I² = 0%, P < 0.001) within half-one-year follow-up (Figure 2D). Echocardiography outcomes representing alterations in structure, in addition, were also focused on. Reduced LVEDV (MD = −24.02 ml, 95% CI: −37.01 to −11.03, P = 0.02) (Figure 2B) and reduced LVESV (MD = −23.47 ml, 95% CI: −37.18 to −9.13, P < 0.001) (Figure 2C) were displayed at the 6-month follow-up, both of which were
NYHA Class Assessment

Three studies indicated the individual change of NYHA class. One study showed that NYHA class of 50% patients were moderately or markedly improved, while another study presented that 69.7% of patients achieved great or moderate improvement (5, 10). The third study only showed that ≥1 NYHA class improvement was accomplished in 46.7% of patients (12). Two studies gave the result of comparison of NYHA class at follow-up vs. that at baseline, and there seemed to be a conflict between the two studies. Sidhu et al. found a significant reduction in NYHA functional class (2.6 ± 0.5 vs. 2.1 ± 0.6; P < 0.001), while Carabelli et al. reported that NYHA functional class was not well improved (2.63 ± 0.51 vs. 2.29 ± 0.95; P = 0.18) (9, 11).

Safety Outcomes

A total of three studies reported complications, which included 53 device- or procedure-related adverse events after implantation (5, 10, 12). Two patient deaths due to peri-procedural pericardial effusion and ventricular fibrillation (VF) during the procedure were reported by Auricchio et al. and Reddy et al., respectively. During the 6-month follow-up, 5 patients with defective transmitter circuitry were reported. No thrombo-embolic strokes occurred, except in one patient with atrial fibrillation (AF) who did not accept anticoagulant therapy. In addition, no lead dislodgements, loss of capture, ventricular septal perforation, device-related infection, or coronary artery injury were observed.

Publication Bias and Sensitivity Analysis

Funnel plot (Figure 3) of the included studies indicated no obvious publication bias. Sensitivity analyses were accomplished by systematically excluding one study at a time, and no single study affected most of the above results.

DISCUSSION

This meta-analysis, by pooling five relevant researches evaluating 175 HF patients, assessed current publications on the efficacy and safety of WiSE CRT in selected patients who failed in conventional CRT or needed a device upgrade. To the best of our knowledge, this study is the first meta-analysis to evaluate the feasibility of WiSE CRT in selected patients, and our results indicated that: (1) WiSE CRT, to some extent, was practical for patients who failed conventional CRT or for those who needed an upgrade; (2) WiSE CRT could conduce to narrow QRSd; (3) WiSE CRT could improve LVEF to a marked extent and be of great help to inhibit the remodeling of heart; (4) WiSE CRT could effectively reduce symptoms of HF patients, which was judged via NYHA class. Considering the above findings, WiSE CRT appears to be a good option for HF patients who fail the conventional CRT or need an upgrade.

WiSE CRT was firstly reported by Auricchio et al., which was a rescue therapy for three patients: (i) a patient needing improved prominently when compared with baseline. Moreover, the fixed-model was applied for the evaluation of echocardiographic index, whereas no heterogeneity was observed (I² = 0).
an upgrade; (ii) a CRT patient whose LV lead does not capture, and (iii) a CRT patient classified as a non-responder, respectively (16). In that case, all three patients were successfully treated with a great improvement in LVEF (from 23.7 ± 3.4% to 39 ± 6.2%; P < 0.017) at the 6-month follow-up. Subsequently, Auricchio et al. carried on the first multicenter, prospective study on the feasibility, safety, and short-term outcome of WiSE CRT (10). A total of 17 patients were included and 13 patients were finally analyzed. This study showed that WiSE CRT delivered a great increase in LVEF (from 25 ± 4.0% to 31 ± 7.0%, P < 0.01) during a 6-month follow-up. Another study carried out by Baldeep et al. tried to indirectly compare WiSE CRT implantation with coronary sinus (CS) upgrades achieved by epicardial LV lead placement in the CS (11). The study showed that CS upgrades were more likely to have an absolute change in LVEF with less burden of comorbidities. However, the study was not powerful enough to prove whether WiSE CRT was more excellent than CS upgrade or not since it did not compare CS upgrade with WiSE CRT directly. Considering the aims of our studies, we finally decided to include one retrospective study after carefully reviewing and evaluating the quality of it (11). Improvement of chamber volume and EF observed in our meta-analysis indicated that WiSE CRT might be an effective strategy for resynchronization therapy and it can be a good rescue therapy for patients with HF who failed traditional CRT or needed an upgrade. The SOLVE-CRT (Stimulation Of the Left Ventricular Endocardium for Cardiac Resynchronization Therapy, NCT02922036), which contained 350 HF patients is an international, multicenter, randomized, double-blind, sham-controlled trial of patients with Class I and IIa indications for CRT who have either failed to respond to or have been unable to receive conventional CRT, and therapeutic effects of WiSE CRT on LVEF and clinical outcomes may have been recently published (17).

However, two deaths were observed in these studies. One patient died as a result of long-time resuscitation, and another one resulted from pericardial effusion, which might be related to the process of procedures. During the initial implantation in patients, there was a risk of pericardial tamponade due to myocardial injury, and hence patients should be selected carefully before implantation and those with high risks such as myocarditis should be evaluated carefully. Also, 5 patients with defective transmitter circuitry were reported, which indicates that further development of
the device is needed. Additionally, more than 50 adverse events were observed in these studies. These problems could be eliminated by the further development of the implantation procedure.

WiSE CRT is an innovative technology to achieve endocardial LV resynchronization wirelessly by a subcutaneous ultrasound pulse generator. A new technical approach called ultrasound-mediated stimulation is applied, while the mean ultrasound-mediated pacing threshold mechanical index it utilizes was only 0.5, which is far away from the index needed for imaging (18). Due to the endocardial stimulation site, stimulation can be simultaneous and biventricular, which is the reason why WiSE CRT can achieve narrower QRSd. On the one hand, the advantages of WiSE CRT lie in a very small, completely endothelialized left ventricular electrode, which itself does not require a battery, and other components of the system are extravascular, so they are easy to be removed in the event of infection and without higher risks. On the other hand, WiSE CRT system provides LV endocardial resynchronization pacing without the need for permanent oral anticoagulation. Moreover, WiSE CRT, unlike traditional pacemakers, is not vulnerable to interference from the use of electromagnetic energy sources due to ultrasound transmission (19). WiSE CRT system is therefore a potentially interesting device for the group of CRT upgrade candidates. It is also an interesting rescue therapy for those so-called non-responders or patients who have failed conventional CRT. So far, all researches related to WiSE CRT have paid attention to “non-responder” and patients who need an upgrade, and no trials directly compare WiSE CRT with conventional CRT, so it remains to be seen which patients are the most interesting population for WiSE CRT, and whether this new technology will be superior to conventional CRT or not. Hence, more related clinical trials are needed to explore the application conditions of WiSE CRT.

His-bundle pacing (HBP) was firstly reported by Deshmukh et al. (20). HBP has emerged as an ideal form of physiological pacing as it activates the normal cardiac conduction system resulting in synchronized contraction of ventricle. Left bundle branch pacing (LBBP), as an alternative way to overcome the limitations of HBP such as lead stability, higher threshold, and early battery depletion, provides low and stable pacing threshold, lead stability, and correction of distal conduction system disease (21). Both of them are more and more popular due to their ability to accomplish physiological pacing. However, the procedural process of HBP and LBBP are complex, and comorbidities such as septum perforation, conduction system injury, and septal artery injury need to be addressed. To some extent, WiSE CRT system can finish simultaneously pacing
without damage to the septum, which enables it to avoid those comorbidities theoretically. However, whether WiSE CRT is superior to HBP or LBBP is not clear, and no relevant research has been found so far. So more clinical trials which compare WiSE CRT with HBP or LBBP are needed to explore the superiority of WiSE CRT.

Feasibility, as it has been shown in resynchronization therapy, WiSE CRT has its limitations. Firstly, ultrasound intensities may be decreased by attenuation, refraction, or reflection of acoustic energy from the rib or lung during the procedure due to inappropriate use of transthoracic echocardiography, which will ultimately have a bad effect on the longevity of the battery (16). Though the battery life has been extended to about 4 years so far, there is an urgent need to make this system more efficient and to develop its battery further. Secondly, WiSE-CRT system requires 2 chest wall incisions and retrograde arterial access, which will predispose to infectious complications. Thirdly, whether the WiSE-CRT system can achieve left bundle branch pacing and the efficacy of left bundle branch pacing operated by it is still unknown, even though endocardial pacing may potentially be more beneficial due to site-specific pacing theoretically. Fourthly, all studies related to WiSE-CRT selected patients who were no-responding to CRT or needed an upgrade, and no trials have directly compared WiSE-CRT with conventional CRT. So whether WiSE-CRT can be superior to conventional CRT is still unclear. Last but not least, injections to left ventricles such as left ventricle perforation and pericardial effusion would occur if the sheath is manipulated inappropriately during the anchor of the electrode, especially in those patients with diffuse myocardial disease (16, 22).

LIMITATIONS

Our meta-analysis has some limitations. Firstly, the number of included patients was quite limited, and the included studies were non-randomized trials, which may reduce the power to validate our findings. Secondly, patients included in the studies were all followed up for 6 months, and so the potential clinical benefits from a longer follow-up duration is unknown. Besides, as we mentioned before, heterogeneity was found when we analyzed QRSd which might result from the measurement of QRSd.

CONCLUSION

Results of this meta-analysis of current studies suggest that leadless endocardial LV pacing resynchronization appears to be a promising method of rescue therapy for HF patients who failed to conventional CRT or needed a device upgrade. WiSE CRT is of great possibility to achieve narrow QRSd and to improve remodeling of the heart. However, WiSE CRT should be developed further to extend its application. Also, more related clinical trials are needed to explore the most interesting population for WiSE CRT and whether WiSE CRT is superior to conventional CRT or physiological pacing such as LBBP or HBP.

AUTHOR CONTRIBUTIONS

JC designed the study. JC and YL performed the database search, study identification, quality evaluation, data extraction, and drafted the manuscript. JC and SL performed the statistical analyses. All authors interpreted the results, revised, and approved the submission of the manuscript.

REFERENCES

1. McIntister FA, Ezekowitz J, Hooton N, Vandermeer B, Spooner C, Dryden DM, et al. Cardiac resynchronization therapy for patients with left ventricular systolic dysfunction: a systematic review. JAMA. (2007) 297:2502–14. doi: 10.1001/jama.297.22.2502
2. Sohaib SM, Chen Z, Whinnett ZI, Bouri S, Dickstein K, Linde C, et al. Meta-analysis of symptomatic response attributable to the pacing component of cardiac resynchronization therapy. Eur J Heart Fail. (2013) 15:1419–28. doi: 10.1093/eurjhf/hft139
3. Bleeker GB, Schalij MJ, Bax JJ. Importance of left ventricular lead position in cardiac resynchronization therapy. Eur Heart J. (2007) 28:1182–3. doi: 10.1093/eurheartj/ehm085
4. Seifert M, Schau T, Moeller V, Neuss M, Meyhoefer J, Butter C. Influence of pacing configurations, body mass index, and position of coronary sinus lead on frequency of phrenic nerve stimulation and pacing thresholds under cardiac resynchronization therapy. Europace. (2010) 12:961–7. doi: 10.1093/europace/euq119
5. Reddy VY, Miller MA, Neuzil P, Sogaard P, Butter C, Seifert M, et al. Cardiac resynchronization therapy with wireless left ventricular endocardial pacing: the SELECT-LV Study. J Am Coll Cardiol. (2017) 69:2119–29. doi: 10.1016/j.jacc.2017.02.039
6. Butter C, Fehrendt S, Möller V, Seifert M. Sendonlose endokardiale linksventrikuläre Stimulation: WiSE™ CRT-System: Alternative zu herkömmlichen Verfahren [Leadless endocardial ultrasound based left ventricular stimulation: WiSE CRT System: alternative to conventional methods]. Herzschrittmacherther Elektrophysiol. (2018) 29:340–348. doi: 10.1007/s00399-018-0605-8
7. Sidhu BS, Lee AWC, Haberland U, Rajani R, Niederer S, Rinaldi CA. Combined computed tomographic perfusion and mechanics with predicted activation pattern can successfully guide implantation of a wireless endocardial pacing system. Europace. (2020) 22:298. doi: 10.1093/europace/euaa227
8. Stieniewicz BJ, Gould J, Porter B, Sidhu BS, Behar JM, Claridge S, et al. Optimal site selection and image fusion guidance technology to facilitate cardiac resynchronization therapy. Expert Rev Med Devices. (2018) 15:555–70. doi: 10.1080/17434440.2018.1502084
9. Carabelli A, Jabeur M, Jaco P, Rinaldi CA, Leclercq C, Rovaris G, et al. European experience with a first totally leadless cardiac resynchronization therapy pacemaker system. Europace. (2021) 23:740–7. doi: 10.1093/europace/euaa342
10. Auricchio A, Delnoy PP, Butter C, Brachmann J, Van Erven L, Spitzer S, et al. Feasibility, safety, and short-term outcome of leadless ultrasound-based endocardial left ventricular resynchronization in heart failure patients: results of the wireless stimulation endocardially for CRT (WiSE-CRT) study. Europace. (2014) 16:681–8. doi: 10.1093/europace/eu435
11. Sidhu BS, Stieniewicz B, Gould J, Elliott MK, Mehta V, Betts TR, et al. Leadless left ventricular endocardial pacing for CRT upgrades in previously failed and high-risk patients in comparison with coronary sinus CRT upgrades. Europace. (2021) 23:1577–85. doi: 10.1093/europace/eub156
12. Okabe T, Hummel JD, Bank AJ, Niazi IK, McGrew FA, Kindsvater S, et al. Leadless left ventricular stimulation with WiSE-CRT
Cang et al. WiSE System for CRT

System—initial experience and results from phase I of SOLVE-CRT Study (nonrandomized, roll-in phase). Heart Rhythm. (2022) 19:22–9. doi: 10.1016/j.hrthm.2021.06.1195

13. Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. (2010). Available online at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp

14. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. (2002) 21:1539–58. doi: 10.1002/sim.1186

15. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. (1997) 315:629–34. doi: 10.1136/bmj.315.7109.629

16. Auricchio A, Delnoy PP, Regoli F, Seifert M, Markou T, Butter C, et al. First-in-man implantation of leadless ultrasound-based cardiac stimulation pacing system: novel endocardial left ventricular resynchronization therapy in heart failure patients. Europace. (2013) 15:1191–7. doi: 10.1093/europace/eut124

17. Singh JP, Abraham WT, Auricchio A, Delnoy PP, Gold M, Reddy VY, et al. Design and rationale for the stimulation of the left ventricular endocardium for cardiac resynchronization therapy in non-responders and previously untreated patients (SOLVE-CRT) trial. Am Heart J. (2019) 217:13–22. doi: 10.1016/j.ahj.2019.04.002

18. Echt DS, Cowan MW, Riley RE, Brisken AF. Feasibility and safety of a novel technology for pacing without leads. Heart Rhythm. (2006) 3:1202–6. doi: 10.1016/j.hrthm.2006.06.012

19. Lee KL, Lau CP, Tse HF, Echt DS, Heaven D, Smith W, et al. First human demonstration of cardiac stimulation with transcutaneous ultrasound energy delivery: implications for wireless pacing with implantable devices. J Am Coll Cardiol. (2007) 50:877–83. doi: 10.1016/j.jacc.2007.04.081

20. Deshmukh P, Casavant DA, Romanyszyn M, Anderson K. Permanent, direct His-bundle pacing: a novel approach to cardiac pacing in patients with normal His-Purkinje activation. Circulation. (2000) 101:869–77. doi: 10.1161/01.cir.101.8.869

21. Huang W, Su L, Wu S, Xu L, Xiao F, Zhou X, et al. A novel pacing strategy with low and stable output: pacing the left bundle branch immediately beyond the conduction block. Can J Cardiol. (2017) 33:1736.e1–1736.e3. doi: 10.1016/j.cjca.2017.09.013

22. Sieniewicz BJ, Betts TR, James S, Turley A, Butter C, Seifert M, et al. Real-world experience of leadless left ventricular endocardial cardiac resynchronization therapy: a multicenter international registry of the WiSE-CRT pacing system. Heart Rhythm. (2020) 17:1291–7. doi: 10.1016/j.hrthm.2020.03.002

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Cang, Liu, Zhu, Liu, Shen, Miao, Zhou and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.